German firms outline "consultancy" role
This article was originally published in Clinica
Against a backdrop of continued under-investment in German healthcare, medical technology companies - and their customers - are looking increasingly to alternative financing instruments to ensure that the product of their R&D enters into commercial circulation.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.